Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SGN-15: Phase II

Preliminary results from an open-label U.S. Phase II trial in 62 patients comparing SGN-15 in combination with

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE